Clinical Trial Update: An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) [Phase 3]

View source ↗

Summary

Phase 3 extension study of lirentelimab in eosinophilic gastritis and eosinophilic duodenitis completed; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Duodenitis
• Eosinophilic Gastritis

Drugs mentioned

• lirentelimab (lirentelimab)

Snippet

Sponsor: Allakos Inc. | Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Status: COMPLETED | Results posted: 2024-04-18